top of page
LATEST NEWS
Estuary Launches With $103 Million to Bring Gene Therapy to Polycystic Kidney Disease
Estuary Biotherapeutics launched with $103 million to develop one-time, kidney-directed AAV gene therapies for ADPKD, the most common inherited kidney disease. Here is how restoring polycystin proteins could stop, or even reverse, kidney cysts.
6 days ago4 min read
Should Gene Therapy Be Used for Common Diseases? Two Cardiologists Propose Five Questions
One-time genetic treatments are moving from rare diseases to common ones like high cholesterol. In JAMA Internal Medicine, two University of Michigan cardiologists explain why permanence, rare side effects and cost call for a new framework.
6 days ago4 min read
Optogenetic Gene Therapy Gives Some Blind Patients Back a Sense of Light
In the NEJM-published PIONEER trial, an algae-derived light-sensing gene plus amber-light goggles improved light sensitivity in 6 of 10 people with late-stage retinitis pigmentosa, and 4 of 8 got better at finding objects. Here is how optogenetics works.
Oct 115 min read
LEARN MORE
LEARN MORE
GENE TECH TIMES
The Future Has Arrived
$430 Million Cell and Gene Therapy Center Set to Launch on Long Island, NY
Governor Kathy Hochul has announced New York Biogenesis Park, a $430 million cell and gene therapy hub set to transform the field on Long Island. Backed by a $150 million state investment, this 700,000-square-foot facility in Lake Success will focus on developing life-saving therapies, including treatments for cancer, genetic diseases, and chronic illnesses. The park will revolutionize medicine by repairing damaged DNA, modifying mutated genes, and engineering therapeutic cel
Dec 2, 2024
bottom of page